Announcement of the availability of Sartorius Stedim Biotech Group's Half-Year Report January to June 2014

Regulatory News:

Sartorius Stedim Biotech (Paris:DIM):

The Sartorius Stedim Biotech Group’s Half-Year Report for the period of January to June 2014 is now available at http://www.sartorius-france.fr/en/company/investor-relations/sartorius-stedim-biotech-sa/

It contains the following information:

- Business development for the first six months and the 2014 forecast for the Sartorius Stedim Biotech Group

- Consolidated financial statements for the period ended June 30, 2014

À propos de Sartorius Stedim Biotech

Sartorius Stedim Biotech is a leading provider of cutting-edge equipment and services for the development, quality assurance and production processes of the biopharmaceutical industry. Its integrated solutions covering fermentation, cell cultivation, filtration, purification, fluid management and lab technologies are supporting the biopharmaceutical industry around the world to develop and produce drugs safely, timely and economically. Sartorius Stedim Biotech focuses on single-use technologies and value-added services to meet the rapidly changing technology requirements of the industry it serves. Strongly rooted in the scientific community and closely allied with customers and technology partners, the company is dedicated to its philosophy of "turning science into solutions.”

Headquartered in Aubagne, France, Sartorius Stedim Biotech is listed on the Eurolist of Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and a global network of sales companies, Sartorius Stedim Biotech enjoys a worldwide presence. Its key manufacturing and R&D site is in Germany. The company employs approx. 3,600 people, and in 2013 earned sales revenue of 588.4 million euros.